Junjie Li, MD, associate chief physician at Fudan University Shanghai Cancer Center, Shanghai, China, talks with Saba Shaikh, MD, about the HER2-directed antibody-drug conjugate SHR-A1811 in the neoadjuvant treatment of HER2-positive early breast cancer.
▷ Estimated Read Time:
1–2 minutes
SABCS Snippets: SHR-A1811 in the Neoadjuvant Treatment of HER2-positive Early Breast Cancer
Connect with thousands of basic and translational scientists, multidisciplinary clinicians, regulatory and pharmaceutical partners, survivors, and patient advocates at the 49th annual San Antonio Breast Cancer Symposium. Complete your registration by Friday, September 25, to take advantage of discounted early registration rates.
Share: